Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer

Condition:   Head and Neck Cancer
Intervention:   Drug: 68Ga-NOTA-AE105
Sponsor:   Rigshospitalet, Denmark
Recruiting - verified November 2016

http://ift.tt/2f58i8C